Forgot details?

Return to login form

Review of Registry and Randomised Comparisons of Zotarolimus-eluting and Sirolimus-eluting Coronary Stents in Western Denmark

REVIEW, June 2010, VOL I ISSUE II, ISSN 2042-4884
10.5083/ejcm.20424884.06 , Cite or Link Using DOI
Creating a Digital Object Identifier Link

A digital object identifier (DOI) can be used to cite and link to electronic documents. A DOI is guaranteed never to change, so you can use it to link permanently to electronic documents.

To find a document using a DOI

  1. Copy the DOI of the document you want to open.
    The correct format for citing a DOI is as follows: doi:10.1016/S0140-6736(08)61345-8
  2. Open the following DOI site in your browser:
  3. Enter the entire DOI citation in the text box provided, and then click Go.
    The document that matches the DOI citation will display in your browser window.

The DOI scheme is administered by the International DOI Foundation. Many of the world's leading publishers have come together to build a DOI-based document linking scheme known as CrossRef.

Michael Maeng MD PhD, Anne Kaltoft MD PhD, Hans-Henrik Tilsted MD, Jan Ravkilde MD DMSci, Lisette O Jensen MD PhD DMSci, Per Thayssen MD DMSci, Niels R Holm MD, Evald H Christiansen MD PhD, Lars R Krusell MD, Christian J Terkelsen MD PhD et all

The safety and efficacy of coronary stents utilised for treatment of ischaemic heart disease have been extensively evaluated. In comparison with bare metal stents, first-generation drug-eluting stents more than halved the need for target lesion revascularisation (TLR). However, the long-term safety has been questioned as the first-generation drug-eluting stents seemed to be associated with a small, but increased, risk of (very) late stent thrombosis.

The latter may be related to an inflammatory reaction caused by the polymer used for drug release control. The second-generation zotarolimus-eluting Endeavor® stent was believed to represent a safer alternative. We present an overview of our results from a large randomised trial and a large registry, both of which compared clinical outcomes with the Endeavor® and the first-generation sirolimus-eluting Cypher® stent. Both studies indicated that the Endeavor® stent had higher risks of adverse outcomes. We discuss these data in the light of the current available data from other randomised comparisons of these two drug-eluting stents.